Clinical Trial Detail

NCT ID NCT02574455
Title ASCENT-Study of Sacituzumab Govitecan in Refractory/Relapsed Triple-Negative Breast Cancer (ASCENT)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Immunomedics, Inc.
Indications

triple-receptor negative breast cancer

Therapies

Sacituzumab govitecan-hziy

Capecitabine + Eribulin + Gemcitabine + Vinorelbine

Age Groups: adult senior

No variant requirements are available.